Cargando…

Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx

Tumor heterogeneity may impact immunohistochemical (IHC) interpretation, thus potentially affecting decision making by treating oncologists for cancer patient management. Programmed cell death ligand-1 (PD-L1) IHC 22C3 pharmDx is a companion diagnostic used as an aid in identifying patient eligibili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalpakoff, Megan, Hund, Stephanie, Musser, Jeanette, Roach, Charlotte, Apostolaki, Angeliki, Vilardo, Monika, Peltz, Lindsay, Watts, Brittany, LaPlaca, Chris, Tabuena-Frolli, Siena, DiMaio, Michael A., Welcher, Rosanne, Kulangara, Karina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505133/ https://www.ncbi.nlm.nih.gov/pubmed/33973887 http://dx.doi.org/10.1097/PAI.0000000000000941

Ejemplares similares

Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications
por: Vainer, Gilad, et al.
Publicado: (2023)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
por: Crager, Michael, et al.
Publicado: (2022)

Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types
por: Krigsfeld, Gabriel S, et al.
Publicado: (2020)

PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs
por: Park, Yujun, et al.
Publicado: (2020)

An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1
por: Cogswell, John, et al.
Publicado: (2016)

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
por: Feldman, Didi, et al.
Publicado: (2023)

Immunohistochemistry (IHC) staining of in-vitro cancer cell-generated tumoroids
por: Amereh, Meitham, et al.
Publicado: (2023)

P53 IHC Result as a Prognostic Tool in MDS
por: Rezvani, Alireza, et al.
Publicado: (2023)

Automated sequential chromogenic IHC double staining with two HRP substrates
por: Petersen, Kenneth Heesche, et al.
Publicado: (2018)

IHC Color Histograms for Unsupervised Ki67 Proliferation Index Calculation
por: Geread, Rokshana S., et al.
Publicado: (2019)

IHC expression of AKT in different grades of epithelial dysplasia: An in vitro study
por: Rani, A. Sandhya, et al.
Publicado: (2022)

Streamlining the use of IHC in identifying germline mismatch repair mutations in Lynch syndrome
por: Rea, Gillian, et al.
Publicado: (2012)

VEGF: A critical driver for angiogenesis and subsequent tumor growth: An IHC study
por: Kapoor, Prakhar, et al.
Publicado: (2012)

Automated Protein Localization of Blood Brain Barrier Vasculature in Brightfield IHC Images
por: Soans, Rajath E., et al.
Publicado: (2016)

Single-cell transcriptomic analysis of mIHC images via antigen mapping
por: Govek, Kiya W., et al.
Publicado: (2021)

Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics
por: Śledzińska, Paulina, et al.
Publicado: (2022)

Predicting IHC staining classes of NF1 using features in the hematoxylin channel
por: Zhang, Wei, et al.
Publicado: (2023)

MALDI-IHC-Guided In-Depth Spatial Proteomics: Targeted and Untargeted MSI Combined
por: Claes, Britt S. R., et al.
Publicado: (2023)

Accuracy of p16 IHC in Classifying HPV-Driven OPSCC in Different Populations
por: Gallus, Roberto, et al.
Publicado: (2023)

Microsatellite Status Detection of Colorectal Cancer: Evaluation of Inconsistency between PCR and IHC
por: Chen, Jielin, et al.
Publicado: (2023)

SEM, TEM, and IHC Analysis of the Sinus Node and Its Implications for the Cardiac Conduction System
por: Mandrioli, D., et al.
Publicado: (2013)

P62/Ubiquitin IHC Expression Correlated with Clinicopathologic Parameters and Outcome in Gastrointestinal Carcinomas
por: Mohamed, Amr, et al.
Publicado: (2015)

A Sensitive IHC Method for Monitoring Autophagy-Specific Markers in Human Tumor Xenografts
por: He, Helen, et al.
Publicado: (2016)

Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?
por: Payandeh, Mehrdad, et al.
Publicado: (2017)

Targeted RNA‐sequencing assays: a step forward compared to FISH and IHC techniques?
por: Tachon, Gaëlle, et al.
Publicado: (2019)

Quantitative immunohistochemistry (IHC) analysis of biomarker combinations for human esophageal squamous cell carcinoma
por: Gao, Jiebing, et al.
Publicado: (2021)

MALDI HiPLEX-IHC: multiomic and multimodal imaging of targeted intact proteins in tissues
por: Lim, Mark J., et al.
Publicado: (2023)

Comparison of the IHC Markers CD138 and CD43 in Oral Leukoplakia: An Original Research
por: Akkaloori, Anitha, et al.
Publicado: (2023)

PMCA screening of retropharyngeal lymph nodes in white-tailed deer and comparisons with ELISA and IHC
por: Benavente, Rebeca, et al.
Publicado: (2023)

Evaluating programmed death‐ligand 1 (PD‐L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study
por: Cerbelli, Bruna, et al.
Publicado: (2021)

Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status
por: Rüschoff, Josef, et al.
Publicado: (2022)

A pathologist-in-the-loop IHC antibody test selection using the entropy-based probabilistic method
por: Shin, Dmitriy, et al.
Publicado: (2012)

TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays
por: Lin, Ching-Hung, et al.
Publicado: (2015)

Nuclear IHC enumeration: A digital phantom to evaluate the performance of automated algorithms in digital pathology
por: Niazi, Muhammad Khalid Khan, et al.
Publicado: (2018)

The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
por: Taube, Janis M, et al.
Publicado: (2020)

Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers
por: Sun, Zhaoyu, et al.
Publicado: (2021)

Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer
por: Barton, S, et al.
Publicado: (2012)

Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer
por: Sui, Weiguo, et al.
Publicado: (2009)

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer
por: Phillips, Therese, et al.
Publicado: (2015)

Study of C-MYC amplification and expression in Iranian gastric cancer samples using CISH and IHC methods
por: Khaleghian, Malihea, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_iifiuge95g0h5vuhfrv2ds3rq6